Laboratory and clinical studies of sparfloxacin

Yuutoku Kinjo, Kyouko Furugen, Yuei Irabu, Hiroshi Fukuhara, Hiroaki Nakamura, Hiroshi Kaneshima, Katsuyoshi Simoji, Keizou Kitsukawa, Yoshiteru Sigeno, Atsushi Saito, Isamu Nakasone, Shinko Taira, Nobuchika Kusano, Seitetsu Hokama, Akihiro Morishima

Research output: Contribution to journalArticlepeer-review


We performed laboratory and clinical evaluations of sparfloxacin, a new oral quinolone, with the following results. 1 ) Antimicrobial activity The minimum inhibitory concentrations (MICs) of sparfloxacin for a total of 309 clinically isolated strains were determined and compared with those of tosufloxacin, ofloxacin, and ciprofloxacin, using the MIC-2000 system. Sparfloxacin had wide antimicrobial activities to clinically isolated strains except methicillin-sensitive Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa. Especially, sparfloxacin showed better MICsto Streptococcus pneumoniae than the compared antimicrobial agents. 2 ) Clinical efficacy Sparfloxacin (300 mg/day) was administered to 1 patient with bacterial pneumonia and 1 patient with chronic bronchitis two times per day. Four patients with chronic bronchitis were treated with sparfloxacin (300 mg) in once a day medication. Clinical responses were excellent in 1 patient, and good in 5 patients. Clinical efficacy rate was 100%. One strain of Haemophilus influenzae was isolated and eradicated. Side effects, and abnormally altered laboratory findings were not observed in all patients.

Original languageEnglish
Pages (from-to)378-384
Number of pages7
Publication statusPublished - 1991
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology


Dive into the research topics of 'Laboratory and clinical studies of sparfloxacin'. Together they form a unique fingerprint.

Cite this